EYElena Nikolaevna Yakusheva

Elena Nikolaevna Yakusheva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena Nikolaevna Yakusheva has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effects of Mexidol on cerebral mitochondrial biogenesis following acute cerebrovascular events

    by A.V. Shchulkin, I.V. Chernykh, Yu.V. Abalenikhina, S.O. Solotnova, E.N. Yakusheva

    Objective. To evaluate the effect of Mexidol on cerebral mitochondrial biogenesis during middle cerebral artery (MCA) occlusion-reperfusion. Material and methods. Male Wistar rats were used in this study. Focal cerebral ischemia was induced by endovascular occlusion-reperfusion of the right MCA following J. Koizumi’s method (1986), with an occlusion period of 60 minutes. At reperfusion onset, animals received a single intravenous injection of either saline or ethylmethylhydroxypyridine succinate (Mexidol) at 50 mg/kg. Relative levels of mitochondrial respiratory chain enzymes and regulatory transcription factors in the ischemic hemisphere were measured at 4, 8, and 24 hours post-reperfusion using Western blot analysis. Results. MCA occlusion-reperfusion did not affect the levels of the transcription factors Nrf1 and TFAM or the proteins NDUFV2, SDHA, MT-CYB, and COX2 in the ischemic hemisphere. However, PGC-1α and ATP5A1 were significantly reduced (p<0.05). Mexidol administration 4 hours after ischemia induction increased PGC-1α and ATP5A1 at 8 hours, as well as PGC-1α, NDUFV2, SDHA, and ATP5A1. At 24 hours, Nrf1, TFAM, PGC-1α, SDHA, and ATP5A1 levels were significantly elevated (p<0.05) compared with the control group. Conclusions. Single intravenous administration of Mexidol at 50 mg/kg at reperfusion onset following 60-minute MCA occlusion in rats is associated with increased levels of PGC-1α, TFAM, Nrf1, NDUFV2, SDHA, and ATP5A1 in the ischemic region. These findings support the hypothesis that Mexidol modulates mitochondrial biogenesis markers.

  • Open Access

    Development and validation of a method for the quantitative determination of succinate in rat blood plasma by HPLC-MS/MS

    by P. Yu. Mylnikov, A. S. Esenina, I. V. Chernykh, A. S. Polupanov, A. V. Shchulkin, E. N. Yakusheva, П. Ю. Мыльников, А. С. Есенина, И. В. Черных, А. С. Полупанов, et al.

    Relevance. Succinate is a central metabolite of the Krebs cycle and also a regulator of numerous processes via the specific succinate receptor SUCNR1. Succinate is an important component of several pharmacological preparations. However, its pharmacokinetics following the administration of these substances remain poorly understood. A sensitive analytical method is required to perform such studies. Objective. To develop and validate a method for the quantitative determination of succinate in rat blood plasma. Methods. The analysis was performed using HPLC-MS/MS — an Ultimate 3000 TSQ Fortis system and a UCT Selectra C18 column (4.6 mm × 100 mm, 3 µm, 100 Å). The separation temperature was 35 °C, and the flow rate was 0.5 mL/min. A gradient elution mode was used with a mixture of 0.1 % aqueous formic acid and 0.1 % formic acid in methanol. The injection volume was 5 µL. For sample preparation, methanol containing chloramphenicol at a concentration of 10 ng/mL as an internal standard was used. A model matrix was used during validation. For succinate detection, the following mass transitions were used in negative ionization mode: 117 m/z → 98.7 m/z, 117 m/z → 73.1 m/z. Results. The method demonstrated selectivity, sensitivity, accuracy, precision, and linearity in the concentration range of 200–20,000 ng/mL. No carryover or matrix effect was observed. The recovery rate was over 96 %. Succinate was stable under the employed storage conditions. Conclusion. A method for the quantitative determination of succinate in rat blood plasma has been developed and validated. This method can be used to analyze endogenous succinate concentrations and the pharmacokinetics of succinate following the administration of succinate-containing drugs.

  • Изучение плазменной концентрации соталола для повышения эффективности и безопасности антиаритмической лекарственной терапии: систематический обзор

    by Никита Васильевич Ененков, Сергей Владимирович Селезнев, Алексей Владимирович Щулькин, Сергей Степанович Якушин, Елена Николаевна Якушева

    Соталол — антиаритмический препарат с двойным механизмом действия, сочетающий неселективную блокаду β-адренорецепторов и блокаду K+-каналов. Несмотря на высокую эффективность, этот препарат характеризуется узкой терапевтической широтой и возможным риском удлинения интервала QT с развитием пируэтной тахикардии. Целью настоящей работы является систематический анализ данных о связи плазменной концентрации соталола с показателями его эффективности и безопасности. Поиск литературы проводили в базах данных PubMed/MEDLINE и eLibrary в соответствии с рекомендациями PRISMA (глубина поиска 1976 – 2023 гг.). В итоговый анализ включено 12 клинических исследований, содержащих данные о плазменных или сывороточных концентрациях соталола, клинических исходах (контроль ритма) и профиле безопасности. Результаты демонстрируют существенную вариабельность данных по диапазонам концентраций, методам определения и исследуемым когортам. Антиаритмический эффект наблюдался в широком диапазоне концентраций (340 – 3440 нг/мл), однако клинически значимое удлинение QTc отмечалось при уровнях 2550 нг/мл, а эпизоды torsades de pointes — при концентрациях выше 3100 нг/мл. Эффективная блокада β-адренорецепторов реализуется в концентрациях порядка 650 – 800 нг/мл. Из-за гетерогенности исследований однозначно выделить терапевтический диапазон концентраций соталола в настоящее время невозможно. Безопасное применение препарата требует персонифицированного подхода.

  • Experimental substantiation of in vivo methods for evaluating substrates and modulators of BCRP transporter protein activity

    by M. I. Povetko, P. Yu. Mylnikov, A. V. Shchulkin, E. N. Yakusheva

    Relevance. BCRP (Human Breast Cancer Resistance Protein) (ABCG2, MXR; ABCP) is an efflux ATP-dependent transporter protein that plays a crucial role in the pharmacokinetics of a wide range of drugs. To enhance therapeutic safety and predict potential pharmacokinetic drug-drug interactions, international regulatory bodies recommend testing medicinal substances for their affiliation with substrates and inhibitors of BCRP. Preclinical studies are primarily conducted using cell lines that overexpress BCRP in vitro. Objective. The aim was to develop and experimentally validate a methodology for assessing medicinal substances as substrates or modulators of BCRP activity in vivo. Materials and methods . Six sexually mature male rabbits of the Soviet Chinchilla breed, weighing between 3000 g and 4000 g, were used in this study. Sulphasalazine was chosen as the classical substrate for BCRP and was administered intragastrically at a dose of 125 mg/kg. Pharmacokinetic evaluation involved blood sampling from ear veins at time points 0.25 h; 0.5 h; 1 h; 1.5 h; 2 h; 3 h; 5 h; 8 h; 12 h; and 24 h post-administration. Quercetin, known as a potent inhibitor of the transporter, was also administered either as a single dose (100 mg/kg) or chronically (25 mg/kg daily for seven days). After both acute and chronic quercetin administration, sulphasalazine was reintroduced, and its pharmacokinetics were assessed again. Plasma concentrations of sulphasalazine were analyzed by HPLC-MS/MS. Model-independent methods were employed to calculate pharmacokinetic parameters. Differences among groups were evaluated via analysis of variance, assuming a log-normal distribution of data. Results . With a single administration of the BCRP inhibitor quercetin to rabbits, of all the tested pharmacokinetic parameters of sulfasalazine, only C max significantly increased, while the remaining parameters (AUC 0-t ; AUC 0-∞ and T1/2) did not significantly change (p > 0.05). With the course administration of the BCRP inhibitor, a significant increase in Cmax values was observed by 3.1 times, AUC 0-t and AUC 0-∞ by 2.81 times (p = 0.0048**) and 2.49 times (p = 0.0192*), respectively, of the sulfasalazine transporter substrate, indicating a decrease in BCRP activity. In this case, inhibition depends on the duration of quercetin administration, which is confirmed by a significant difference in pharmacokinetic parameters between a series of single and course injections of the substance (p < 0.05). Conclusion . An original method has been developed and experimentally validated for testing medicinal compounds as substrates or modulators of BCRP activity in vivo using male Soviet Chinchilla rabbits as test subjects, with sulphasalazine (125 mg/kg) serving as the transporter substrate and quercetin (administered either as a single dose of 100 mg/kg or as a course of 25 mg/kg/day for seven days) as the inhibitor.

  • The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents

    by A.V. Shchulkin, I.V. Chernykh, Y.V. Abalenikhina, M.V. Gatsanoga, D.L. Kochetkova, N.A. Kruzhalov, E.V. Krestinina, E.N. Yakusheva

    Objective. To compare the effects of Mexidol, Cerebrolysin, and Cortexin on the levels of brain-derived neurotrophic factor (BDNF), tumor necrosis factor-alpha (TNFα), and apoptosis markers in the rat brain following middle cerebral artery (MCA) occlusion-reperfusion. Material and methods. The study was performed on male Wistar rats. Right MCA occlusion-reperfusion was modeled using the method of J. Koizumi (1986). The occlusion duration was 60 minutes (1 hour). At the onset of reperfusion, animals were administered a single intravenous injection of either saline (control), or Mexidol (ethylmethylhydroxypyridine succinate) intravenously at a dose of 50 mg/kg, or Cerebrolysin intraperitoneally at a dose of 215 mg/kg, or Cortexin intraperitoneally at a dose of 1 mg/kg. Twenty-four hours after the start of reperfusion, the brain lesion volume was analyzed after staining with a 1% solution of 2.3,5-triphenyltetrazolium chloride. Western blotting was used to assess the levels of BDNF, TNFα, and apoptosis markers (Fas, bax, caspase 3) in the ischemic hemisphere. Five animals were included in each group for biochemical studies. Results. In the MCA occlusion-reperfusion model, the necrosis volume in the affected hemisphere of control animals was 38.16±5.98%. Mexidol reduced the necrosis volume to 20.48±2.33% (p<0.001), Cerebrolysin — to 32.57±3.31% (p=0.176), Cortexin — to 32.75±4.91% (p=0.198). Modeling the pathology triggered the development of neuroinflammation — an increase in TNFα content, activation of apoptosis — increased levels of Fas, bax, and caspase 3, and did not affect the BDNF level. Administration of Mexidol increased the BDNF level in the ischemic hemisphere and reduced the content of Fas, bax, caspase 3, and TNFα. Cerebrolysin had a similar effect, although less pronounced. Cortexin did not affect the BDNF level but reduced the content of TNFα, Fas, and bax. Conclusion. Thus, when administered at the onset of reperfusion following MCA occlusion, Mexidol exerts the most pronounced cerebroprotective effect, stimulating neurogenesis and suppressing the development of neuroinflammation and apoptosis.

  • A pharmacoeconomic study of captopril, enalarpil, and lisinopril using data from the State Register of Maximum Selling Prices

    by E.E. Izigina, E.N. Yakusheva, G.B. Artemyeva, D.S. Titov, D.P. Bokova

    Introduction. Arterial hypertension (AH) is a serious problem of modern medicine. High blood pressure significantly increases the risk of dangerous cardiovascular complications. Aim. To perform a pharmacoeconomic cost-effectiveness analysis of angiotensin-converting enzyme inhibitors (ACE inhibitors) – captopril, enalapril, and lisinopril using data from the State Register of Maximum Selling Prices. Materials and methods. Data on the clinical effectiveness of the studied ACE inhibitors was obtained from literature sources. The level of reduction of elevated blood pressure (systolic and diastolic) was considered as the criterion of clinical efficacy. The costs of pharmacotherapy were calculated based on the data from the State Register of Medicines. To perform a cost-effectiveness analysis (CEA), the cost-effectiveness ratio (CER) was calculated for captopril, lisinopril, and enalapril in order to determine the most cost-effective ACE inhibitor with the minimum CER value. The CEA was performed in 3 variants: CEA No. 1 – calculation of CER for 20 subgroups (CER separately for each dose that demonstrated clinical effectiveness); CEA No. 2 – calculation of CER separately for each dose, the price of which was used to calculate the costs; CEA No. 3 – calculation of CER for all doses simultaneously. Results. The CER values for enalapril at a daily dose of 20 mg, achieved by taking four 5 mg tablets, were statistically significantly lower than the CER values for captopril and lisinopril when assessing clinical effectiveness by normalizing systolic blood pressure (SBP). It was also found that the CER values for enalapril at a daily dose of 20 mg (8 tablets at a dose of 2,5 mg) were statistically significantly lower than the CER values for captopril and lisinopril when assessing clinical effectiviness by normalizing diastolic blood pressure (DBP). Conclusion. A cost-effectiveness analysis of ACE inhibitors showed that enalapril 20 mg/day is more cost-effective than captopril and lisinopril for normalizing SBP and DBP.

  • Transfected Cell Lines as a Tool for Studying the Functioning of SLC Transporters in Pharmacology

    by Yuliya V. Abalenikhina, Aleksey V. Shchulkin, Pelageya D. Ananyeva, Pavel Yu. Mylnikov, Svetlana O. Solotnova, Ekaterina A. Zatsarinnaya, Elena N. Yakusheva, Kristina G. Pereverzeva, Valentina I. Zvyagina

    INTRODUCTION: Transporter proteins play a key role in cellular transport of bioactive substances and drugs, regulating their influx (SLC transporters) and efflux (ABC transporters). Of particular interest are OATP1B1 and OATP1B3, members of the SLC transporter family, expressed in hepatocytes and responsible for transport of endogenous compounds and xenobiotics. Their impaired function due to genetic polymorphisms or drug interactions can lead to changes in the pharmacokinetics, toxicity and decreased therapeutic effectiveness. However, investigation of these transporters is impeded by the absence of optimal cell models reproducing their activity in vivo. Primary hepatocytes, despite their physiological relevance, have limited viability in culture, and standard cell lines (e.g., HepG2) exhibit low OATP expression. Therefore, transfected cell lines such as HEK293-OATP1B1/B3 are becoming a critical tool for research, despite the need for further validation and optimization of culture conditions. AIM: To carry out the comparative analysis of cell lines expressing OATP1B1/B3 and evaluate the role of transfected cells. MATERIALS AND METHODS: The article presents a literature review of PubMed, Medline, Springer, eLibrary databases, as well as relevant scientific articles retrieved using Google Scholar. The obtained relevant information is consolidated, structured and analyzed to examine the role of transfected cellular models expressing OATP1B1/B3. CONCLUSION: Literature data demonstrate that the use of transfected cell lines enables the separate study of transport activity, standardization of experiments and high-throughput screening of substrates and inhibitors. Transfected cells remain indispensable for preclinical studies facilitating the development of personalized medicine and creation of safe medical drugs.

  • Open Access

    Non-achievement of therapeutic range of antihypertensive drug concentration in a triple combination as a cause of ineffective control of primary arterial hypertension: ambiguous results of a cross-sectional clinical trial in routine clinical practice

    by Sergey V. Seleznev, Aleksey V. Shchulkin, Elena N. Yakusheva, Sergey S. Yakushin, Pavel Y. Mylnikov, Natalia N. Nikulina, Yulia V. Abalenikhina, Nina D. Mzhavanadze, Щулькин Алексей Владимирович, Якушин Сергей Степанович

    INTRODUCTION: High blood pressure (BP) is one most important risk factor for coronary heart disease, stroke, chronic kidney disease, and dementia. Despite a wide range of pharmacological and non-pharmacological treatments, BP control can be achieved in less than 50% of cases, therefore, the development of new methods to improve the effectiveness of arterial hypertension (AH) treatment is urgent. One possible approach is monitoring antihypertensive drug (AHD) for their correspondence to the therapeutic range (TR). AIM: To analyze the effect of serum concentrations of lisinopril, indapamide and amlodipine on blood pressure parameters in patients with stage III essential hypertension taking these drugs in a triple combination. METHODS: A cross-sectional clinical study included 147 patients with stage III essential hypertension who were simultaneously receiving the three studied AHDs (lisinopril, amlodipine, indapamide); mean age (63.7±11.0) years; 44% were men; 54% of patients had uncontrolled hypertension. Using high-performance liquid chromatography with tandem mass spectrometry (Ultimate 3000 chromatograph and TSQ Fortis mass spectrometer (ThermoFisher, USA)) the concentrations of AHDs in blood serum were analyzed: steady-state concentration (C0h) and 2 hours after administration of AHDs (C2h). Using univariate and then multivariate regression analysis, the existence of a relationship between the mean level of daytime and nighttime blood pressure, pharmacokinetic parameters (C0h, C2h, achievement of TR) and general clinical criteria (age, gender, body weight, creatinine clearance) was determined. RESULTS: The proportion of patients with C0h below TR was: 8.2% for lisinopril, 27.9% for amlodipine, 69.4% for indapamide, 8.8% for simultaneous indapamide and amlodipine, and 0.7% for the three simultaneous AHDs. The proportion of patients with non-achievement of the target BP level was the following: with C0h of lisinopril within the TR (n=135) — 56.0%, with C0h of lisinopril below the TR (n=12) — 33.0%, with C0h of amlodipine within the TR (n=106) — 57.0%, with C0h of amlodipine below the TR (n=41) — 49.0%, with C0h of indapamide within the TR (n=45) — 44.0%, with C0h of indapamide below the TR (n=102) — 59.0%, with C0h of indapamide and amlodipine simultaneously below the TR (n=13) — 85.0%, with C0h of the three drugs simultaneously below the TR (n=1) — 1 out of 1. According to the results of multiple regression analysis, a significant factor influencing the level of daytime SBP was age, daytime DBP — age and non-achievement of the TR of amlodipine and indapamide C0h; of nighttime SBP — body weight, of nighttime DBP — age and non-achievement of the TR of amlodipine and indapamide C0h. CONCLUSION: A high prevalence of subtherapeutic serum concentrations of indapamide and amlodipine has been recorded. Non-achievement of the TR level of both amlodipine and indapamide is associated with higher diastolic blood pressure with no significant effect on systolic blood pressure. The problem of poor hypertension control cannot be explained solely by serum antihypertensive drug concentrations — no convincing, unambiguous correlation has been established.

  • Open Access

    Structural and functional biochemistry of OATP1B3: from polymorphisms to therapeutic targets

    by Yuliya V. Abalenikhina, Pelageya D. Ananyeva, Aleksey V. Shchulkin, Ekaterina D. Mikryukova, Pavel Y. Mylnikov, Anna E. Mezina, Elena N. Yakusheva, Ананьева Пелагея Дмитриевна, Щулькин Алексей Владимирович

    INTRODUCTION: Organic Anion Transporting Polypeptide 1B3 (OATP1B3) plays a key role in hepatic transport of endogenous compounds, xenobiotics and drugs. In recent years, new data have been presented on the molecular organization, mechanisms of function and regulation, genetic polymorphisms of OATP1B3, and its clinical significance in pharmacokinetics, diagnosis and treatment. Of particular interest is the extrahepatic expression of the transporter, which opens new prospects for targeted therapy. AIM: To identify the structural and functional biochemical features of OATP1B3 transporter, its genetic polymorphisms and their impact on pharmacokinetic and therapeutic properties, determine the potential of OATP1B3 for targeted and personalized medicine. Literature search was conducted using the following keywords: OATP1B3, SLCO1B3, transporter, substrate specificity, regulation, oncology, and hepatocellular carcinoma in Russian and English. Electronic databases providing access to peer-reviewed scientific articles were used: eLibrary, Medline/PubMed, and Google Scholar. The search was conducted between 2000 and 2004 to cover the current data, starting from the first publications on OATP1B3 identification, but also taking into account earlier key works on OATP1B3 identification. This review presents the biochemical features of OATP1B3 localization, structure, and transport cycle. It also systematizes literature data on substrates, inhibitors, and inducers of the transporter protein, describes regulatory mechanisms and identifies the clinical significance of this transporter protein. OATP1B3 is demonstrated to have tissue-specific localization: it is normally expressed in the liver, but in oncologic pathologies is detected in the cytosol of gastrointestinal and lung tumor cells, where it may participate in signaling pathways. Evidence of high genetic variability of the SLCO1B3 gene is presented. The clinical potential of OATP1B3 is confirmed by its role in diagnostics (liver MRI with gadoxetate) and the possibility of targeted delivery of chemotherapeutic drugs. CONCLUSION: OATP1B3 is an influx transporter protein that has an important clinical significance participating in transport of statins, cytostatics and diagnostic contrast agents, and its activity is modulated by post-translational modifications.


  • Evaluation of the effect of ethylmethylhydroxypyridine succinate on the activity of the BCRP transporter protein in vitro

    by M. I. Povetko, P. Yu. Mylnikov, A. V. Shchulkin, E. N. Yakusheva

    Relevance. Breast cancer resistance protein (BCRP) is one of the main clinically significant transporter proteins that play an important role in the pharmacokinetics of drugs. To predict the development of drug interactions at the level of this transporter, it is recommended to test drugs for belonging to substrates and BCRP inhibitors. Objective. Comparative assessment of the effect of ethylmethylhydroxypyridine succinate (EMHPS) on the activity of the BCRP transporter protein under in vitro conditions using sulfasalazine as a substrate. Materials and methods. The study was performed in vitro on Caco-2 cells that were cultured in a transwell-system. Sulfasalazine was used as a BCRP substrate. EMHPS was used in the concentration range of 0.1 — 500 µM. A classic BCRP inhibitor, quercetin, was used as a comparison drug. The concentration of sulfasalazine in the transport medium was determined by HPLC-MS/MS. Results. During the study, it was shown that EMHPS inhibited BCRP activity in the concentration range of 50–500 µM. In terms of inhibitory activity, the tested drug was inferior to the comparison drug quercetin — the IC 50 of quercetin was 0.2 µM, the IC 50 of EMHPS was 37.5 µM. To study the clinical significance of the inhibitory ability of EMHPS, the ratio C max of EMHPS/IC 50 (predicts systemic inhibition of BCRP in the liver, kidneys, and histohematic barriers) and the ratio dose of EMHPS/ 250 ml / IC 50 (predicts inhibition of BCRP in the intestine) were calculated. It has been shown that EMHPS can clinically significantly inhibit BCRP in the intestine. Conclusion. Thus, EMHPS is an inhibitor of BCRP in vitro . To confirm the significance of the obtained results for the development of drug-drug interactions, it is necessary to conduct clinical studies.